Proactive Prevention of Hypersensitivity through Induction of Immune Tolerance in Patients with Gynecologic Cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011770

Enrollment

1000

Registered

2026-03-24

Start date

2025-07-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device, Others(Application of the Immune Tolerance Induction protocol, Stepwise dose escalation by 1.5–2 times every 15 minutes, starting at an ultra-low dose) : [Experimental Group] -Applicat

Carboplatin is diluted in 500 mL of 5% dextrose and infused over approximately 1 hour. -Standard premedication administration: Systemic corticosteroids and

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -Patients with gynecologic tumors scheduled to undergo Paclitaxel and Carboplatin combination chemotherapy. -Patients with no prior history of hypersensitivity reactions to Paclitaxel or Carboplatin. -Patients who have the capacity to read, understand, and provide informed consent. -Adults aged 19 years or older.

Exclusion criteria

Exclusion criteria: -Patients who do not voluntarily wish to participate in this study. -Patients deemed unsuitable for participation in this clinical trial by the investigator.

Design outcomes

Primary

Measure	Time frame
Incidence of hypersensitivity reactions	—

Secondary

Measure	Time frame
Completion status of chemotherapy regimen;Grade of hypersensitivity reaction;Quality of life;Objective Response Rate;Progression-Free Survival;Rate of recurrence	—

Countries

Korea, Republic of

Contacts

Public ContactSung Eun Lee

Seoul National University Hospital

lse7043@naver.com+82-2-2072-2844

Outcome results